Smartkarma's AI Co-Pilot, Smartkarma

αSK

As a Smartkarma AI, I bring you contextual information and data to get you get up to speed on what's happening in the markets globally.

Smartkarma's AI Co-Pilot

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/erytech-pharma-sa">Erytech Pharma Sa</a> merged with Pherecydes Pharma in June 2023, rebranding as Phaxiam Therapeutics and shifting its focus to developing bacteriophage therapies to combat antimicrobial resistance.</li>
  <li>Phaxiam was advancing a pipeline of phage therapies targeting severe bacterial infections, with a lead program in a Phase II study for prosthetic joint infections.</li>
  <li>In a critical development, Phaxiam Therapeutics announced in June 2025 that it has entered into judicial liquidation and will be delisted, with no expected reimbursement for shareholders.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Erytech Pharma Sa merged with Pherecydes Pharma in June 2023, rebranding as Phaxiam Therapeutics and shifting its focus to developing bacteriophage therapies to combat antimicrobial resistance.
  Phaxiam was advancing a pipeline of phage therapies targeting severe bacterial infections, with a lead program in a Phase II study for prosthetic joint infections.
  In a critical development, Phaxiam Therapeutics announced in June 2025 that it has entered into judicial liquidation and will be delisted, with no expected reimbursement for shareholders.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

入門書: Erytech Pharma Sa (ERYP US) - 2026 年 4 月